Zydus Wellness posts 30% profit growth in FY25, Q4 net sales up 17% YoY

For the quarter ended March 31, 2025, Zydus Wellness reported 17% year-on-year growth in net sales at ₹9,106 million, up from ₹7,780 million in Q4 FY24. Adjusted net profit after tax for the quarter was ₹1,719 million, an increase of 14.4% over the previous year. Quarterly EBITDA grew 17.1%, from ₹1,622 million to ₹1,900 million.

The company attributed its performance to continued marketing investments and the strong momentum of key brands including Nutralite, Glucon-D, Everyuth, and Nycil. The Food and Nutrition segment posted a quarterly growth of 15.4% and annual growth of 13% in FY25.

Following its 100% acquisition of Naturell (India) Private Limited, the newly integrated business is performing as expected.

Key brand performance during the year reflected continued market leadership across categories. The Sugar Free brand maintained its dominant position in the sugar substitute segment with a market share of 95.9%, reaffirming its leadership status. Similarly, Glucon-D retained its number one rank in its category, holding a market share of 58.8% at the MAT level.

While the overall Nutrition Drink category registered a decline of 2.1%* at the MAT level, Complan maintained its presence with a 4%* market share. Meanwhile, the company continued to strengthen and diversify its Nutralite product portfolio, building on innovation and distribution.

The Personal Care segment showed strong momentum with consistent double-digit growth. For Q4, the segment grew by 22.5%, while the full-year growth stood at 33.4%. Within this, Nycil remained the market leader in the prickly heat powder category with a share of 33.8%. Everyuth Scrub also sustained its leadership position, increasing its market share to 48.5%, a rise of 321.4 basis points compared to the same period last year.

The Everyuth brand further expanded into new segments with the launch of Sheet Masks in three variants—Golden Glow, Anti-Pollution, and Aloe Cucumber. Everyuth Peel Off continued to dominate its category with a 77.7%* share, reflecting a growth of 6.1 basis points. In the broader facial cleansing segment, Everyuth was ranked fifth with a 7.7%* market share.

Related Posts

Cancer cure must not be hostage to Big Pharma

In recent years, immunotherapy has expanded the limits of cancer treatment. Therapies that harness the body’s immune system to fight malignant cells have improved survival rates in cancers once considered…

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Pune:- A woman, 34, dia­gnosed with poly­cystic ovary syn­drome, or PCOS, as a teen­ager, saw her first nat­ural men­strual cycle in Feb­ru­ary—six months after start­ing Moun­jaro for weight man­age­ment. This…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients